Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 7—July 2014

Candida auris–Associated Candidemia, South Africa

Cite This Article

To the Editor: We noted the report by Chowdhary et al. (1) and report Candida auris as a causative agent of candidemia in South Africa, with an estimated prevalence of 0.3% (N.P. Govender et al., unpub. data). First isolated in 2009, C. auris is an emerging species associated with clinical disease (26). We analyzed 4 isolates submitted to the National Institute for Communicable Diseases (Johannesburg, South Africa) from 4 patients with candidemia who had been admitted to different public- and private-sector hospitals from October 2012 through October 2013.

Identification of the isolates was undertaken by using ChromAgar Candida medium (Mast Diagnostics, Merseyside, UK), Vitek-2 YST (bioMérieux, Marcy ľEtoile, France), API 20C AUX (bioMérieux), and sequencing of internal transcribed spacer (ITS) and D1/D2 domains of the ribosomal RNA gene (7), followed by microbroth dilution susceptibility testing (8). All isolates were misidentified as C. haemulonii and Rhodotorula glutinis by Vitek-2 YST and API 20C AUX assays, respectively (Table).

Similar to the findings of Chowdhary et al., all isolates assimilated N-acetyl-glucosamine (1). With the use of the CBS-KNAW database, pairwise sequence alignment of ITS region showed 99% sequence homology to Kuwait isolates, and alignment of D1/D2 domain showed 98% homology to the Kuwait/India isolates (9). In a neighbor-joining phylogenetic tree based on ITS sequences, South Africa isolates formed a cluster with India and Kuwait isolates (Technical Appendix Figure).

Fluconazole MICs were high for all isolates (Table). Isolates 209 and 224 showed reduced voriconazole susceptibility with MICs of 1 μg/mL and 2 μg/mL, respectively, which is above the epidemiologic cutoff value for 11 Candida species (10). Isolates were susceptible to amphotericin B and echinocandins at low MICs Clinical data were available for 1 patient (Technical Appendix Table). Two C. haemulonii isolates were identified during laboratory-based sentinel surveillance for candidemia in South Africa; the ITS region of one isolate was sequenced and the isolate identified as C. auris (N.P. Govender, pers. comm.). In this study, C. auris was misidentified by routinely used tests and was accurately identified by sequencing, in keeping with previous findings (1,3,4,6).



We thank Serisha Naicker for technical assistance.

The work was supported by the National Institute for Communicable Diseases. N.P.G. has received honoraria from MSD (Pty) Ltd South Africa (Merck) and Pfizer for speaking engagements and has received a research grant from Pfizer South Africa.


Rindidzani E. Magobo, Craig Corcoran, Sharona Seetharam, and Nelesh P. GovenderComments to Author 
Author affiliations: National Institute for Communicable Diseases, Johannesburg, South Africa (R.E. Magobo, N.P. Govender); National Health Laboratory Service, Johannesburg, South Africa (S. Seetharam); University of the Witwatersrand, Johannesburg (S. Seetharam, N.P. Govender); Ampath National Reference Laboratory, Pretoria, South Africa (C. Corcoran)



  1. Chowdhary  A, Sharma  C, Duggal  S, Agarwal  K, Prakash  A, Kumar Singh  P, New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis. 2013;19:16703 . DOIPubMedGoogle Scholar
  2. Satoh  K, Makimura  K, Hasumi  Y, Nishiyama  Y, Uchida  K, Yamaguchi  H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:414. DOIPubMedGoogle Scholar
  3. Kim  MN, Shin  JH, Sung  H, Lee  K, Kim  EC, Roy  N, Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009;48:e5761. DOIPubMedGoogle Scholar
  4. Lee  WG, Shin  JH, Uh  Y, Kang  MG, Kim  SH, Park  KH, First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49:313942. DOIPubMedGoogle Scholar
  5. Oh  BJ, Shin  JH, Kim  MN, Sung  H, Lee  K, Joo  MY, Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. Med Mycol. 2011;49:98102. DOIPubMedGoogle Scholar
  6. Chowdhary  A, Kumar  VA, Sharma  C, Prakash  A, Agarwal  K, Babu  R, Multidrug resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2013. Epub ahead of print.
  7. White  TJ, Bruns  T, Lee  S, Taylor  J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols: a guide to methods and applications. San Diego: Academic Press; 1990. p. 315–22.
  8. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 3rd ed. Wayne (PA): The Institute; 2008.
  9. CBS-KNAW Fungal Biodiversity Centre. Pairwise sequence alignment tool [cited 2013 Nov 1].
  10. Pfaller  MA, Diekema  DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50:284656. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid2007.131765

Related Links


Table of Contents – Volume 20, Number 7—July 2014


Please use the form below to submit correspondence to the authors or contact them at the following address:

Nelesh P. Govender, National Institute for Communicable Diseases–Centre for Opportunistic, Tropical and Hospital Infections, Private Bag X4, Sandringham, 2132, South Africa

Send To

10000 character(s) remaining.


Page created: May 29, 2014
Page updated: May 29, 2014
Page reviewed: May 29, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.